Apex Biotechnology Corp.
TWSE:1733.TW
29.15 (TWD) • At close November 1, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) TWD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 1,676.537 | 2,244.176 | 2,131.656 | 2,005.337 | 2,198.862 | 2,043.614 | 1,795.3 | 1,763.284 | 1,847.454 | 1,788.929 | 1,829.221 | 2,026.086 | 1,876.273 | 1,749.69 | 1,438.917 |
| Cost of Revenue
| 1,145.421 | 1,667.337 | 1,560.144 | 1,553.113 | 1,608.285 | 1,483.512 | 1,363.786 | 1,286.441 | 1,300.319 | 1,264.256 | 1,260.778 | 1,217.724 | 1,127.066 | 995.811 | 826.474 |
| Gross Profit
| 531.116 | 576.839 | 571.512 | 452.224 | 590.577 | 560.102 | 431.514 | 476.843 | 547.135 | 524.673 | 568.443 | 808.362 | 749.207 | 753.879 | 612.443 |
| Gross Profit Ratio
| 0.317 | 0.257 | 0.268 | 0.226 | 0.269 | 0.274 | 0.24 | 0.27 | 0.296 | 0.293 | 0.311 | 0.399 | 0.399 | 0.431 | 0.426 |
| Reseach & Development Expenses
| 163.325 | 165.448 | 153.289 | 150.771 | 155.123 | 116.382 | 101.257 | 93.04 | 102.181 | 105.029 | 109.148 | 98.228 | 88.391 | 82.456 | 65.69 |
| General & Administrative Expenses
| 119.989 | 118.777 | 109.86 | 100.602 | 109.87 | 107.271 | 94.867 | 60.965 | 71.299 | 71.721 | 68.441 | 65.494 | 63.938 | 63.719 | 60.224 |
| Selling & Marketing Expenses
| 104.269 | 116.054 | 106.909 | 97.885 | 121.968 | 109.1 | 74.391 | 76.949 | 72.86 | 58.436 | 41.863 | 42.045 | 39.241 | 33.679 | 37.068 |
| SG&A
| 224.258 | 234.831 | 216.769 | 198.487 | 231.838 | 216.371 | 169.258 | 137.914 | 144.159 | 130.157 | 110.304 | 107.539 | 103.179 | 97.398 | 97.292 |
| Other Expenses
| -389.4 | 27.836 | -7.897 | 15.173 | -30.711 | -54.892 | -39.847 | -185.653 | 20.845 | 37.143 | 104.43 | 24.336 | 12.74 | 20.397 | 0.905 |
| Operating Expenses
| 389.4 | 400.279 | 370.058 | 349.258 | 386.961 | 332.753 | 270.515 | 230.954 | 246.34 | 235.186 | 219.452 | 205.767 | 191.57 | 179.854 | 162.982 |
| Operating Income
| 141.716 | 204.973 | 193.971 | 120.528 | 172.905 | 227.349 | 160.999 | 245.889 | 300.795 | 289.487 | 348.991 | 602.595 | 557.637 | 574.025 | 449.461 |
| Operating Income Ratio
| 0.085 | 0.091 | 0.091 | 0.06 | 0.079 | 0.111 | 0.09 | 0.139 | 0.163 | 0.162 | 0.191 | 0.297 | 0.297 | 0.328 | 0.312 |
| Total Other Income Expenses Net
| -0.754 | -5.398 | -9.035 | -9.913 | -9.965 | -66.004 | -49.025 | -193.803 | 10.498 | 29.455 | 77.388 | -6.932 | 37.916 | -41.245 | -22.658 |
| Income Before Tax
| 140.962 | 199.575 | 184.936 | 110.615 | 162.94 | 161.345 | 111.974 | 52.086 | 311.293 | 318.942 | 426.379 | 595.663 | 595.553 | 532.78 | 426.803 |
| Income Before Tax Ratio
| 0.084 | 0.089 | 0.087 | 0.055 | 0.074 | 0.079 | 0.062 | 0.03 | 0.168 | 0.178 | 0.233 | 0.294 | 0.317 | 0.304 | 0.297 |
| Income Tax Expense
| 25.248 | 18.124 | -17.353 | 15.986 | 49.962 | 67.687 | 29.577 | 49.13 | 49.755 | 49.945 | 55.536 | 73.217 | 68.936 | 78.831 | 100.32 |
| Net Income
| 115.783 | 181.785 | 202.224 | 94.795 | 113.859 | 95.119 | 85.553 | 3.181 | 261.853 | 273.377 | 371.221 | 522.71 | 526.617 | 453.949 | 326.483 |
| Net Income Ratio
| 0.069 | 0.081 | 0.095 | 0.047 | 0.052 | 0.047 | 0.048 | 0.002 | 0.142 | 0.153 | 0.203 | 0.258 | 0.281 | 0.259 | 0.227 |
| EPS
| 1.16 | 1.82 | 2.03 | 0.95 | 1.14 | 0.85 | 0.86 | 0.03 | 2.66 | 2.77 | 3.77 | 5.41 | 5.51 | 4.74 | 3.41 |
| EPS Diluted
| 1.15 | 1.81 | 1.93 | 0.87 | 1.04 | 0.85 | 0.85 | 0.03 | 2.52 | 2.67 | 3.6 | 5.28 | 5.47 | 4.71 | 3.39 |
| EBITDA
| 222.877 | 299.073 | 289.646 | 225.726 | 289.104 | 278.349 | 230.894 | 163.454 | 433.737 | 441.473 | 529.931 | 686.501 | 686.369 | 602.081 | 505.99 |
| EBITDA Ratio
| 0.133 | 0.133 | 0.136 | 0.113 | 0.131 | 0.136 | 0.129 | 0.093 | 0.235 | 0.247 | 0.29 | 0.339 | 0.366 | 0.344 | 0.352 |